Gerresheimer's Survival Bid Relies on Asset Sale Amid Accounting Crisis

German pharma packaging firm Gerresheimer faces technical default after audit failure, triggering asset sales and a frozen financial calendar as shares collapse.

The share price of German pharmaceutical packaging specialist Gerresheimer has become a barometer of corporate distress. Trading at a mere €17.17, the stock has plummeted 68.47% over the past twelve months, a stark reflection of an escalating accounting scandal that has frozen the company's financial communications and pushed it to the brink of a technical default.

At the heart of the turmoil is the company's inability to produce an audited annual report for 2025, a failure that triggered its expulsion from the SDAX index on April 10. Without that crucial auditor's sign-off, index-tracking funds and institutional investors were forced into automated selling. This compounded selling pressure on shares already down roughly 38% since the start of the year. The refusal of the audit opinion stems from several serious accounting errors, including misbooked lease liabilities of €65.5 million, questionable capitalizations of development costs, and prematurely recognized revenues from bill-and-hold arrangements. The latter alone forces corrections of approximately €35 million in revenue and around €24 million in adjusted EBITDA.

This lack of a certified financial statement has placed Gerresheimer in technical default on its debt covenants, severely complicating the refinancing of over €870 million in maturing Schuldschein loans. The company is now reliant on the forbearance of its lenders. In response, interim CEO Uwe Röhrhoff has initiated a fire sale of assets to secure liquidity. The planned divestment of U.S. subsidiary Centor Inc., a plastics packaging unit for the American pharma market, is central to this strategy. Morgan Stanley is managing the sale process for the business, which carries a book value of about €292 million.

Concurrently, management is pursuing drastic cost-cutting measures, including the planned closure of its Chicago Heights plant by the end of 2026. The company has also warned of non-cash impairments of up to €240 million, a move that would conserve cash flow but significantly erode equity. The official financial calendar has been suspended indefinitely, with the Q1 2026 report and the annual general meeting postponed. This information vacuum has erased a key stability anchor for shareholders.

Despite the profound uncertainty and ongoing investigations by German financial regulator BaFin—now expanded to cover the 2024 and 2025 accounts—some institutional investors are seeing opportunity. Firms like CastleKnight and Deka have been building positions at the depressed price level, positioning themselves against active short sellers. Meanwhile, the German shareholder association DSW is examining legal action against former CEO Dietmar Siemssen and ex-CFO Bernd Metzner.

All forward-looking plans, including management's revenue projection of up to €2.4 billion for 2026, are explicitly conditional on successful refinancing talks. The company faces a critical deadline on July 14, 2026, the scheduled date for its half-year report. By then, the board must present credible figures and signed loan agreements to avert a further collapse in confidence. The proceeds from the Centor sale will determine whether Gerresheimer can appease its creditors and exit technical default, or if its precarious financial flight will end in a crash.